Masahiro Takatani
Overview
Explore the profile of Masahiro Takatani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsumi A, Kato H, Ogawa T, Ueki T, Wato M, Fujii M, et al.
Gastrointest Endosc
. 2024 Mar;
100(1):76-84.
PMID: 38490459
Background And Aims: Cholecystitis can occur after self-expandable metallic stent (SEMS) placement for malignant biliary obstruction (MBO), but the best treatment option for cholecystitis has not been determined. Here, we...
2.
Minoda N, Tada T, Takatani M, Nakamura S, Wani Y
Clin J Gastroenterol
. 2023 Aug;
16(6):931-936.
PMID: 37632657
A 59-year-old female was referred to our hospital for pancreatic tumor. She had undergone resection of uterine fibroids 27 years ago, and leiomyoma in the left thigh 8 years ago....
3.
Matsumoto T, Ikoma T, Yamamura S, Miura K, Tsuduki T, Watanabe T, et al.
Sci Rep
. 2023 Jul;
13(1):11935.
PMID: 37488181
No abstract available.
4.
Hayashino K, Fujiwara Y, Isokane Y, Tobita H, Inomata T, Inokuchi T, et al.
Ann Hematol
. 2023 Jun;
102(9):2625-2626.
PMID: 37340057
No abstract available.
5.
Matsumoto T, Ikoma T, Yamamura S, Miura K, Tsuduki T, Watanabe T, et al.
Sci Rep
. 2023 Feb;
13(1):2433.
PMID: 36765099
Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC....
6.
Matsumoto T, Yamamura S, Ikoma T, Kurioka Y, Doi K, Yasuda T, et al.
Clin Med Insights Oncol
. 2022 Nov;
16:11795549221137135.
PMID: 36408335
Background: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data...
7.
Ikoma T, Matsumoto T, Kurioka Y, Takatani M, Nagai H, Matsumoto Y, et al.
J Clin Med
. 2022 Oct;
11(20).
PMID: 36294421
Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from...
8.
Ikoma T, Shimokawa M, Matsumoto T, Boku S, Yasuda T, Shibata N, et al.
Cancer Immunol Immunother
. 2022 Aug;
72(2):427-435.
PMID: 35927359
Background: In Japan, nivolumab administration is the standard treatment for patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) who are refractory or intolerant to fluoropyrimidines and platinum-based...
9.
Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matsuo Y, et al.
JGH Open
. 2022 Jul;
6(7):462-469.
PMID: 35822120
Background And Aim: The relationship between the characteristics of hepatocellular carcinoma (HCC) diagnosed after sustained virological response (SVR) with direct-acting antiviral (DAA) therapy and surveillance status has not been sufficiently...
10.
Matsumoto T, Yamamura S, Ikoma T, Kurioka Y, Doi K, Boku S, et al.
J Clin Med
. 2022 Apr;
11(8).
PMID: 35456340
Trastuzumab deruxtecan (T-DXd) has shown promising efficacy against positive advanced gastric cancer (AGC). However, data on its real-world efficacy in AGC patients are insufficient, and the predictive marker of T-DXd...